Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Inclusion Criteria: * Had measurable disease according to Standard Diagnostic Criteria at the time of initial Multiple Myeloma diagnosis * Meets criteria for symptomatic multiple myeloma at the time of induction chemotherapy * Is transplant eligible based on clinician judgement * Willing to undergo ASCT in first or second remission * Achieve partial response or better with induction chemotherapy prior to ASCT according to the IMWG Uniform Response Criteria for Multiple Myeloma * Be MRD+ upon restaging prior to stem cell collection and ASCT * Eastern Cooperative Oncology Group (EGOG) performance status score of less than 2 * Life expectancy greater than six months * Have a creatinine clearance \> 45 mL/min/m2 at the time of transplant evaluation * If frozen stem cells from earlier mobilized leukapheresis are unavailable at the time of mobilized leukapheresis, patients must meet parameters/criteria according to institutional SOP for autologous stem cell apheresis * Be willing and clinically stable to undergo stem-cell mobilized and collect enough CD34+ cells sufficient for 2 ASCT per institutional guidelines or investigator discretion or have sufficient frozen cells from a SoC collection prior to signing study consent * Be willing and clinically stable to undergo a non-mobilized MNC-Apheresis while admitted to the hospital to generate CIML NK cells * Be willing to undergo maintenance after ASCT per NCCN guidelines based on disease risk * If a woman of child-bearing potential, …